Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

109.18 -1.93 (-1.74%)

Official Closing Price Updated: 4:10 PM EST, Jan 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

I Correctly Predicted That These 15 Dow Jones Stocks Would Boost Their Payouts in 2025. Here's Why It Can Happen Again in 2026. ↗

Today 14:35 EST

The Dow is chock-full of high-quality companies that pay growing dividends.

Via The Motley Fool

Topics Stocks

Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally

Today 14:11 EST

In a landmark moment for the future of personalized medicine, Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) announced groundbreaking five-year follow-up data on January 20, 2026, for...

Via MarketMinute

Topics Intellectual Property

Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth

Today 11:52 EST

NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the...

Via MarketMinute

Topics Earnings Economy Intellectual Property

MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? ↗

January 21, 2026

Via Stocktwits

Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse

Today 10:54 EST

As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm

January 21, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and...

Via StockStory

Topics Economy Stocks

Why Moderna Stock Surged Today ↗

January 21, 2026

The vaccine maker is expanding beyond its COVID-focused offerings.

Via The Motley Fool

ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗

January 16, 2026

Via Stocktwits

Topics Intellectual Property

Merck & Co. Inc. (NYSE:MRK) Presents a Compelling Value Investment Case ↗

January 14, 2026

Via Chartmill

Merck Shares Rise On $30M Funding From CEPI To Develop Affordable Ebola Vaccine ↗

January 21, 2026

CEPI will provide Merck with $30 million and Merck will, in turn, leverage its joint venture with Wellcome, called Hilleman Laboratories, to develop an Ebola vaccine with an updated manufacturing...

Via Stocktwits

Topics Workforce

Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious ↗

January 20, 2026

BofA Securities said the target hike reflects higher sales expectations, despite logistics challenges.

Via Stocktwits

Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update ↗

January 20, 2026

Intismeran autogene vaccine, in combination with cancer drug Keytruda, reduced the risk of recurrence or death at five years of follow-up, the company said.

Via Stocktwits

GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics

January 20, 2026

In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion....

Via MarketMinute

Topics Intellectual Property

Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following

January 20, 2026

Via ACCESS Newswire

3 “Forever Stocks” to Hold When the Market Won’t Sit Still ↗

January 19, 2026

Via MarketBeat

The New Era of Johnson & Johnson: A 2026 Deep-Dive Research Feature

January 19, 2026

As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its...

Via Finterra

Topics Artificial Intelligence Bankruptcy Economy

3 Profitable Stocks to Consider Right Now

January 18, 2026

Profitable companies tend to be more resilient, giving them the flexibility to invest and return capital to shareholders. Businesses that consistently generate earnings can better navigate downturns...

Via StockStory

The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026

January 16, 2026

As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based...

Via Finterra

Topics Initial Public Offering Intellectual Property Lawsuit

January 15, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape

January 15, 2026

As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic...

Via MarketMinute

Topics Economy Intellectual Property

Healthcare Titan Ascendant: Johnson & Johnson Hits All-Time Highs as It Navigates a New Political and Clinical Era

January 15, 2026

As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Earnings

A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗

January 15, 2026

Via Chartmill

Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot

January 14, 2026

Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period...

Via Finterra

Topics Initial Public Offering Intellectual Property

The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape

January 12, 2026

As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the...

Via MarketMinute

Topics Economy Intellectual Property World Trade

Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B ↗

January 12, 2026

When asked about the company’s strategic transactions, CEO Mark Goldsmith said at a conference that the company has a policy of not commenting on rumors or speculation.

Via Stocktwits

The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance

January 12, 2026

The 44th Annual J.P. Morgan Healthcare Conference opened today in San Francisco with an intensity not seen in years, as the healthcare and technology sectors officially merged their futures. The...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

3 Dividend Stocks to Hold for the Next 10 Years ↗

January 12, 2026

All three companies are in better shape than most investors are (understandably) presuming.

Via The Motley Fool

Topics Bonds

1 Momentum Stock Worth Your Attention and 2 Facing Headwinds

January 11, 2026

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...

Via StockStory

This ETF Is Proof That the Healthcare Rebound Is Real ↗

January 11, 2026

Via MarketBeat

Topics ETFs

Why Revolution Medicines Stock Surged by 11% Today ↗

January 09, 2026

The company might become the latest biotech acquisition story soon.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.